Clinical trials: Tumor Pancreas
Pancreatic Neoplasms, Adenocarcinoma
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
The aims of this protocol are: 1. To study the safety and tolerability of the combination of etanercept and gemcitabine in patients with advanced pancreatic cancer: 2.
- Trial name
- NCT00201838
- Testing
- Gemcitabine, Etanercept
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Liver Cirrhosis, Liver Steatosis
EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI
Aim of this study is to evaluate the correlation between the characteristics detected by the 7T MRI equipment and the histological composition of native explanted livers (group A), liver graft excluded for donation (group B) and…
- Conditions
- Liver Cirrhosis, Liver Steatosis, Hepatocellular Carcinoma, Pancreatic Cancer
- Trial name
- EXLIPSE (NCT04012021)
- Testing
- 7T Magnetic Resonance Imaging
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Pisa
Metastatic Pancreatic Cancer
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel
Inclusion 1. Subjects who are males or females ≥ 19 years of age 2. Subjects who have the following history of first-line gemcitabine and nab-paclitaxel among patients with cytologically or histologically proven metastatic…
- Trial name
- MP-PDAC-01 (NCT03666832)
- Testing
- TEW-7197
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Joon Oh Park
Pancreatic Cancer
Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
The goal of this clinical research study is to learn if Niraparib can help to control metastatic pancreatic cancer. The safety of this drug will also be studied.
- Trial name
- NIRA-PANC (NCT03553004)
- Testing
- Niraparib Treatment
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Kansas Medical Center
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer American Joint Committee on Cancer v8
PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy
This clinical trial tests how well surgical resection after chemotherapy given before surgery to make the tumor smaller (neoadjuvant) works to treat pancreatic cancer that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer American Joint Committee on Cancer v8, Unresectable Pancreatic Adenocarcinoma
- Trial name
- NCT06132087
- Testing
- Biospecimen Collection, Computed Tomography, Distal Pancreatectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer
Study of 124I-NM404 in Advanced Solid Malignancies
The purpose of this study is to assess the use of investigational compound 124I-NM404 for accurate detection and characterization of a wide variety of solid primary and metastatic malignancies anywhere in the body.
- Trial name
- NCT01662284
- Testing
- 124I-NM404
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Advanced Solid Tumor, Metastatic Breast Cancer
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.
- Conditions
- Advanced Solid Tumor, Metastatic Breast Cancer, Metastatic Ovarian Cancer, Metastatic Endometrial Cancer
- Trial name
- NCT06533332
- Testing
- ERX-315
- Where
- 5 sites in Australia
- Volunteers
- 36 people
- Sponsor
- EtiraRx Australia Pty Ltd
Well Differentiated Pancreatic Endocrine Tumor
Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs
Abnormal PI3K-Akt-mTOR (mammalian target of rapamycin) pathway signaling and autocrine activation of the mTOR pathway, mediated through insulin-like growth factor 1 (IGF1), has been implicated in the proliferation of pNET …
- Trial name
- MetNET1 (NCT02294006)
- Testing
- Everolimus plus Octreotide LAR plus Metformin
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Renal Cell Carcinoma, Soft Tissue Sarcoma
HYPAZ: Hypertension Induced by Pazopanib
Pazopanib is a new cancer drug that works by limiting the growth of new blood vessels in tumours. About half of patients who take pazopanib develop high blood pressure (hypertension).
- Conditions
- Renal Cell Carcinoma, Soft Tissue Sarcoma, Glioblastoma, Ovarian Cancer
- Trial name
- HYPAZ (NCT01392352)
- Testing
- Pazopanib
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Cancer Diagnosis, LungCancer
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
The goal of this observational study is to screen and differentiate common cancers in participants with or without suspicious lesions.
- Conditions
- Cancer Diagnosis, LungCancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT06036563
- Where
- 8 sites in China
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Air Force Military Medical University, China
Pancreatic Pseudocyst
A Study to Evaluate the Effectiveness and Safety of EUS-guided Transluminal Drainage With 'Niti-S SPAXUS Stent'
The purpose of this study is to evaluate the safety and effectiveness of endoscopic ultrasound (EUS)-guided transluminal drainage with 'Niti-S SPAXUS Stent' for the treatment of pancreatic pseudocyst.
- Trial name
- NCT02730663
- Testing
- Niti-S SPAXUS Stent
- Where
- 6 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Taewoong Medical Co., Ltd.
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Advanced Metastatic Pancreatic Cancer
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
This study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator. The indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after…
- Trial name
- NCT06662006
- Testing
- nal-IRI,5-fu,LV, benmelstobart, anlotinib
- Where
- China
- Volunteers
- 56 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
PDAC
Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer
CA19-9 is an acidic glycoside containing sialic acid, called ganglioside. Lewis blood group antigen is the precursor for the synthesis of CA19-9, which is formed by the combined action of sialic acid transferase and…
- Trial name
- NCT06515587
- Testing
- Lewis genotype detection reagent
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Cancer
Multicentric Database for KRAS Mutant Pancreatic Cancer
Construction and Maintenance of a Precision Subtyping-Based Clinical Cohort for Targeted Therapy in KRAS-Mutant Pancreatic Cancer
- Trial name
- NCT07557849
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Fudan University
Pancreatic Cancer, Neoadjuvant
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
- Trial name
- NCT06129812
- Testing
- Neoadjuvant treatment
- Volunteers
- 1,132 people
- Sponsor
- Seoul National University Hospital
Pancreatic Cancer
Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer
Single compassionate use subject is an 83 year old woman with a history of lymph node positive breast cancer and recently diagnosed pancreatic cancer in May.
- Trial name
- NCT02851381
- Testing
- FG-3019
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Colorectal Cancer
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic…
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT05163028
- Testing
- HBI-2376
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 42 people
- Sponsor
- HUYABIO International, LLC.
Ppancreatic Cancer
Study on Efficacy and Safety of VMAT Technique With Local Dose Escalation for Unresectable Pancreatic Cancer
The goal of this observational study is to learn about the efficacy and safety of the Volumetric Modulated Arc Therapy (VMAT) dose sculpting technique combined with different radiotherapy doses (local dose escalation vs.
- Trial name
- NCT07242911
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chifeng Tumor Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.